Chlormadinone acetate (CMA) Powder (302-22-7) video
Chlormadinone acetate (CMA) Powder (302-22-7) Specification:
|Chemical Structure:||Product Name: Chlormadinone acetate(CMA)|
|Cas No.: 302-22-7|
|Molecular Formula: C23H29ClO4|
|Molecular Weight: 404.93|
|Storage: Store at room temperature away from light and moisture.|
|Documents(COA & HPLC etc.): Available|
Chlormadinone acetate (CMA) Powder (302-22-7) Description:
Chlormadinone acetate, a synthetic progestogen, was introduced in 1965 as a component in oral contraceptive preparations. Chlormadinone acetate sometimes abbreviated as CMA, and also known as 17α-acetoxy-6-chloro-6-dehydroprogesterone
Chlormadinone Acetate powder is the actetate salt form of chlormadinone, a synthetic progestin with antiandrogenic and antigonadotropic effects. Chlormadinone acetate (CMA) is a potent progesterone receptor (PR) agonist, a partial androgen receptor (AR) antagonist and a weak glucocorticoid receptor (GR) antagonist. Chlormadinone powder binds to PRs, which induces the expression of progesterone-responsive genes. In addition, chlormadinone blocks ARs in target organs and reduces the activity of skin 5 alpha-reductase; thus inhibiting androgen production and signaling. Through the negative feedback action on the hypothalamus-pituitary system, chlormadinone also suppresses gonadotropin secretion, which prevents ovarian and adrenal androgen production. Therefore, this agent decreases endometrial thickness, increases the viscosity of cervical mucus, inhibits ovulation and suppresses follicular growth and maturation.
Chlormadinone acetate is a steroidal progestin with additional antiandrogen and antigonadotropic (and by extension antiestrogenic) effects. CMA powder has been used in the treatment of vaginal bleeding, oligomenorrhea, polymenorrhea, hypermenorrhea, secondary amenorrhea, and endometriosis. It has also been used clinically as a hormonal contraceptive, and in part due to its capacity to lower estrogen levels, but also for improved effectiveness in contraception, chlormadinone has frequently been combined with ethinyl estradiol for this purpose.
- Venner P (1992). “Megestrol acetate in the treatment of metastatic carcinoma of the prostate”. Oncology. 49 Suppl 2 (2): 22–7. doi:10.1159/000227123. PMID 1461622.
- Bouchard P (2005). “Chlormadinone acetate (CMA) in oral contraception–a new opportunity”. The European Journal of Contraception & Reproductive Health Care. 10 Suppl 1: 7–11. doi:10.1080/13625180500434889. PMID 16356876.
- Kanimoto Y, Okada K (November 1991). “[Antiandrogen therapy of benign prostatic hyperplasia–review of the agents evaluation of the clinical results]”. Hinyokika Kiyo (in Japanese). 37 (11): 1423–8. PMID 1722627.
- Besnard–Charvet Christelle (21 October 2014). Homeopatie & perimenopauza. Grada Publishing, a.s. pp. 61–. ISBN 978-80-247-5191-7.